Waters

Shares of Waters Corporation rose to a 52‑week high of $420.3 and are currently trading at $420.77, with a market capitalization of $41.3 billion. Year‑to‑date the stock is up 44.4%. In the second quarter the company beat expectations with adjusted earnings of $3.05 per share (estimate $3.01) and revenue of $1.64 billion (estimate $1.62 billion), but it faces currency headwinds and integration challenges. TD Cowen has upgraded the stock to Buy and raised the price target to $475, while analysts also warn of potential overvaluation. » Plus sur de.investing.com

Waters reported adjusted EPS of $3.05 for Q2 (expectation $3.01) and revenue of $1.645 billion (expectation $1.62 billion). Management raised the full-year guidance for organic revenue growth to 7–9% and adjusted EPS to $14.45–14.65, supported by cost reductions, price increases and product launches. Premarket the stock fell about 1.3% as investors weighed currency effects, acquisition-related charges and the complexity of integrating acquired businesses. Risks remain from currency headwinds, integration efforts and execution of planned price increases. » Plus sur de.investing.com

Waters unveiled the Xevo TQ Absolute XR IVD at the 2026 annual meeting of the Association for Diagnostics & Laboratory Medicine, an LC‑MS/MS system for applications in women’s health, cancer diagnostics and toxicology. According to the company, the device offers up to fivefold greater sensitivity compared with similar systems (Xevo TQ-XS IVD and SCIEX 6500 IVD), enabling lower limits of detection and measurements from smaller sample volumes. The system uses the StepWave XR Ion Guide, which is said to deliver up to six times longer consistency of the ion ratio compared with the previous model, and is part of the MassTrak IVD portfolio including ACQUITY UPLC I-Class PLUS. Waters cites improved signal stability, robustness and potentially lower downtime; the system is now available to order. » Plus sur de.investing.com